The ADRB1 gene encodes the beta-1 adrenergic receptor¹¹ beta-1 adrenergic receptor
The primary catecholamine receptor on cardiac muscle cells, controlling heart rate, contractile force, and cardiac output in response to stress and exercise, the heart's main throttle for sympathetic nervous system signaling. While the Arg389Gly variant (rs1801253) controls how strongly the receptor fires when activated, the Ser49Gly variant at position 49 determines how quickly the receptor is pulled off the cell surface and degraded during sustained catecholamine exposure — a process called agonist-promoted downregulation²² agonist-promoted downregulation
The cell actively removes and destroys receptors from its surface during prolonged stimulation, reducing the signal over time — a built-in brake on excessive activation.

At codon 49, the common A allele encodes serine (Ser49), while the minor G allele encodes glycine (Gly49). About 75% of people worldwide are Ser49 homozygotes; only ~2% carry two copies of the Gly49 allele. Despite its lower frequency, the Gly49 variant has outsized importance: it produces a receptor that shuts itself down faster under stress, lowers resting heart rate by approximately 5 bpm, protects against heart failure mortality, and is overrepresented among endurance athletes.

The Mechanism

The Ser49Gly substitution sits in the extracellular N-terminal domain of the receptor, altering its N-glycosylation³³ N-glycosylation
The addition of sugar chains to the protein, which affects how the receptor is processed, folded, and degraded by the cell pattern. A 2002 trafficking study⁴⁴ 2002 trafficking study
Rathz DA et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol, 2002 found that the Ser49 receptor exists partially as a highly glycosylated ~105 kDa form that is absent in the Gly49 variant. This extra glycosylation protects the receptor from degradation during sustained agonist exposure. After 18 hours of isoproterenol stimulation, the Gly49 receptor lost 24% of its surface density while the Ser49 receptor lost none. When new receptor synthesis was blocked, the Gly49 form showed 55% degradation versus 36% for Ser49 — a substantial difference in receptor turnover rate.

A complementary study⁵⁵ complementary study
Levin MC et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem, 2002 confirmed that the Gly49 receptor also displays higher constitutive (baseline) activity and more rapid desensitization. Paradoxically, this combination of higher initial signaling with faster shutdown appears to be cardioprotective — the receptor self-limits before sustained catecholamine exposure can drive harmful cardiac remodeling.

The Evidence

Resting Heart Rate: A landmark family study of 1,348 individuals⁶⁶ landmark family study of 1,348 individuals
Ranade K et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet, 2002 of Chinese and Japanese descent found a clear additive effect: Ser/Ser homozygotes (AA) had a mean resting heart rate of 69.4 bpm, Ser/Gly heterozygotes (AG) 67.7 bpm, and Gly/Gly homozygotes (GG) 64.2 bpm — a 5.2 bpm gradient (p = 0.0004). The effect size was comparable to beta-blocker therapy, meaning Gly49 homozygotes have a built-in physiological equivalent of low-dose beta-blockade.

Heart Failure Prognosis: The Gly49 allele consistently predicts better heart failure outcomes. A Swedish study of 184 patients⁷⁷ Swedish study of 184 patients
Borjesson M et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J, 2000 found that at 5-year follow-up, 62% of Ser49 homozygotes had died or been hospitalized versus only 39% of Gly49 carriers (HR 2.34 for Ser49, p = 0.003). A Brazilian cohort of 178 patients⁸⁸ Brazilian cohort of 178 patients
Albuquerque FN et al. Ser49Gly beta1-adrenergic receptor genetic polymorphism as a death predictor in Brazilian patients with heart failure. Arq Bras Cardiol, 2020 confirmed the finding: the Gly49 allele reduced death risk by 63% (OR 0.37, p = 0.03).

However, the Ser49 genotype paradoxically predicts stronger LVEF recovery. A study of 98 HF patients⁹⁹ study of 98 HF patients
Luzum JA et al. Association of genetic polymorphisms in the beta-1 adrenergic receptor with recovery of left ventricular ejection fraction in patients with heart failure. J Cardiovasc Transl Res, 2019 found that Ser49 homozygosity was the strongest predictor of LVEF recovery (OR 8.2, 95% CI 2.1-32.9, p = 0.003), independent of beta-blocker use. This likely reflects the Ser49 receptor's resistance to downregulation — it maintains signaling capacity that supports contractile recovery when the failing heart is therapeutically managed.

Endurance Performance: A Polish study of 223 athletes and 354 controls¹⁰¹⁰ Polish study of 223 athletes and 354 controls
Sawczuk M et al. Ser49Gly and Arg389Gly polymorphisms of the ADRB1 gene and endurance performance. Cent Eur J Biol, 2013 found that the Gly49 allele frequency was significantly higher in endurance athletes than controls (11% vs 6.4%, p = 0.026), with an odds ratio of 2.0 (95% CI 1.16-3.47, p = 0.018) for endurance athlete status. Notably, the Gly49:Arg389 haplotype (combining both ADRB1 variants) was also overrepresented among endurance athletes (p = 0.048), suggesting the two variants interact functionally.

Practical Implications

The Ser49Gly variant creates a clinically relevant spectrum: Ser49 homozygotes (AA) have higher resting heart rates, more sustained adrenergic signaling, and greater beta-blocker responsiveness. Gly49 carriers (AG, GG) have intrinsic cardioprotection through enhanced receptor downregulation, lower resting heart rates, and an endurance advantage — but may respond less dramatically to beta-blocker therapy since their receptors already self-regulate.

For heart failure management, both variants matter: Ser49 homozygotes benefit most from aggressive beta-blocker titration (the receptors need pharmacological help to downregulate), while Gly49 carriers have better natural prognosis regardless of treatment.

Interactions

ADRB1 Ser49Gly interacts with Arg389Gly (rs1801253) to form functionally distinct haplotypes. The Ser49/Arg389 combination produces the highest-activity receptor — resistant to downregulation (Ser49) and maximally coupled to G-protein signaling (Arg389). This haplotype may identify individuals with the strongest catecholamine drive and greatest potential benefit from beta-blocker therapy.

The Gly49/Arg389 haplotype was specifically overrepresented among endurance athletes (Sawczuk et al. 2013), combining the enhanced receptor downregulation of Gly49 with the higher coupling efficiency of Arg389 — a profile that may optimize cardiac performance under sustained exercise by providing both strong initial response and effective self-regulation.

Parvez et al. (2012) demonstrated haplotype-level effects in atrial fibrillation rate control: patients with the Ser49/Gly389 haplotype had the best response to rate-control medications (67% responders vs ~50% for other haplotype groups, p < 0.001).

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults over 65 worldwide, and the complement factor H gene (CFH) harbors the strongest known genetic risk signals for this disease. rs1831282 is an intronic variant located at chromosome 1q31.3, position 196,704,862 (GRCh38), within the CFH gene — lying between the well-characterized Y402H coding variant (rs1061170) and the synonymous haplotype tag rs2274700. In the Naj et al. 2013 GWAS¹¹ Naj et al. 2013 GWAS
Genetic factors in nonsmokers with AMD revealed through genome-wide gene-environment interaction analysis. Ann Hum Genet. 2013, rs1831282 reached genome-wide significance within the CFH region (P=7.51×10⁻³⁰), with GWAS Catalog recording odds ratios of 2.38–2.63 per C allele copy for AMD risk.

Unusually for an AMD risk variant, the common (major) allele at rs1831282 is the risk allele. The C allele occurs at approximately 60% global frequency and tags the complement-dysregulation haplotype, while the rarer A allele (~40%) is the GRCh38 reference and the protective allele. This means the majority of the population — particularly East Asians (~94% C allele frequency) — carry at least one copy of the AMD-risk allele at this locus.

The Mechanism

CFH encodes the primary fluid-phase and cell-surface brake on the alternative complement pathway²² alternative complement pathway
the complement system's continuously active arm that must be tightly regulated to avoid attacking healthy tissue; CFH accelerates breakdown of the C3 convertase (C3bBb) to prevent amplification cascades. The retinal pigment epithelium (RPE) and Bruch's membrane sit at the interface between the retinal photoreceptors and the choriocapillaris blood supply — and they depend heavily on CFH to suppress chronic, low-grade complement activation driven by accumulated oxidized lipids, cellular debris, and advanced glycation end-products that accumulate with normal aging.

rs1831282 does not alter the CFH protein sequence. Its AMD association arises through linkage disequilibrium³³ linkage disequilibrium
the tendency for alleles at nearby positions to be inherited together; high LD means variants track one another across generations with functionally important nearby variants. The C allele marks the same complement-dysregulation haplotype block captured by rs1329428, rs2274700, and (to a lesser extent) rs1061170 — all of which are associated with reduced CFH protective function at retinal surfaces. Li et al. 2006⁴⁴ Li et al. 2006
CFH haplotypes without the Y402H coding variant show strong association with AMD susceptibility. Nat Genet. 2006 demonstrated that noncoding CFH variants carry AMD risk independently of Y402H, explaining why intronic variants like rs1831282 show genome-wide significance even in the absence of amino acid changes.

The Evidence

The primary evidence for rs1831282 comes from the Naj et al. 2013 genome-wide analysis⁵⁵ Naj et al. 2013 genome-wide analysis
1,207 AMD cases and 686 controls of Caucasian ancestry; 668,238 SNPs genotyped, which identified three genome-wide significant AMD loci: CFH (P=7.51×10⁻³⁰), ARMS2 (P=1.94×10⁻²³), and RDBP/CFB/C2 (P=4.37×10⁻¹⁰). The GWAS Catalog records two separate analysis sets from this study, both pointing to rs1831282 in the CFH region — one with OR=2.38 (95% CI 2.08–2.78, P=1×10⁻³¹) and one with OR=2.63 (95% CI 2.17–3.13, P=9×10⁻²⁴), with risk allele frequencies of 0.53–0.55 — consistent with the C allele carrying the risk signal.

The landmark Klein et al. 2005 Science paper⁶⁶ landmark Klein et al. 2005 Science paper
Complement factor H polymorphism in age-related macular degeneration. Science. 2005 established CFH as the primary AMD gene through a genome-wide scan of 116,204 SNPs in 96 cases and 50 controls, finding the intronic CFH variant rs380390 as the lead signal. Homozygous risk carriers showed 7.4-fold increased AMD odds (95% CI 2.9–19). rs1831282, located in the same CFH gene, resides within the haplotype block that Klein et al. and subsequent fine-mapping studies have identified as carrying multiple independent AMD risk signals.

As of 2025, emerging complement-targeted therapies for AMD — including the C3 inhibitor pegcetacoplan and the C5 inhibitor avacincaptad pegol — make CFH genotyping increasingly relevant. Heesterbeek et al. 2020⁷⁷ Heesterbeek et al. 2020
797 AMD patients, 945 controls; complement activation quantified across AMD disease stages. Invest Ophthalmol Vis Sci. 2020 found that CFH variants predict complement activation levels, supporting the use of genetic stratification to identify patients most likely to benefit from complement inhibitor therapy.

Practical Actions

For CC homozygotes — approximately 36% of the global population — this intronic CFH variant contributes to elevated AMD risk through the same complement-dysregulation mechanism as Y402H and other CFH haplotype markers. The additive architecture of the CFH locus means risk compounds across these variants, so individuals with multiple CFH risk alleles should prioritize early retinal monitoring. Supplementation with lutein, zeaxanthin, and omega-3 fatty acids has a documented evidence base for AMD risk reduction across all CFH haplotype risk genotypes.

Interactions

rs1831282 lies within the CFH haplotype block also tagged by rs1329428, rs2274700, and rs551397. These variants are in partial to moderate linkage disequilibrium with each other and with the Y402H coding variant (rs1061170). The risk signal from rs1831282 partially overlaps with — but is not fully interchangeable with — Y402H: Li et al. 2006⁸⁸ Li et al. 2006
Nat Genet. 2006 showed noncoding CFH haplotypes carry AMD risk independently of Y402H, and in East Asian populations where Y402H is rare, non-coding CFH variants like rs1831282 may carry the primary CFH risk signal. ARMS2 variants (rs10490924) operate through a distinct oxidative-stress pathway and compound with CFH risk alleles to give the highest AMD risk combinations documented.

FOXO3 encodes the most consistently replicated longevity gene in human genetics. But not every variant within FOXO3 is a longevity signal — and rs2153960 illustrates that distinction with unusual clarity. This intronic SNP does not itself associate with exceptional lifespan in large meta-analyses, yet it sits at a locus whose biological output — modulation of circulating insulin-like growth factor 1 (IGF-1) — is directly connected to how FOXO3 protein exerts its anti-aging effects. Understanding rs2153960 means understanding the IGF-1/FOXO3 axis that makes FOXO3 one of the most consequential longevity genes ever identified.

Kaplan et al. 2011¹¹ Kaplan et al. 2011
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet. 2011 conducted a GWAS of 10,280 middle-aged and older adults from four community cohorts, finding a borderline genome-wide significant association between rs2153960 and serum IGF-1 concentration (p = 5.1 × 10⁻⁷), and noting that this locus was "associated with longevity." The signal was subsequently confirmed at full genome-wide significance in a larger meta-analysis of 30,884 European-ancestry adults across 21 studies, which explicitly described rs2153960 as "the known longevity-associated variant (FOXO3)" and highlighted it as evidence for "the IGF axis in mediating effects of known (FOXO3) and novel longevity-associated loci."

The Mechanism

The insulin/IGF-1 signaling (IIS) pathway is evolution's primary master regulator of lifespan across metazoans — the same pathway that extends lifespan in nematodes, flies, mice, and is associated with human longevity. FOXO3 sits at the nexus of this pathway: when IGF-1 levels are low, the PI3K-AKT cascade is inactive, FOXO3 remains unphosphorylated and translocates to the nucleus, where it activates hundreds of genes involved in oxidative stress resistance, DNA repair, autophagy, and controlled apoptosis of damaged cells. When IGF-1 is high, AKT phosphorylates FOXO3 and traps it in the cytoplasm, silencing its protective program.

rs2153960 lies in intron 2 of FOXO3, a 101,625 base-pair noncoding region that contains multiple independent regulatory elements. As an intronic variant with no confirmed functional characterization (unlike rs2802292, which has a demonstrated HSF1 binding site mechanism), rs2153960 likely tags a nearby regulatory element that influences either FOXO3 expression or a gene in the same chromatin domain. The A allele associates with higher circulating IGF-1 at genome-wide significance. Higher IGF-1 means more AKT activation, more FOXO3 nuclear exclusion, and attenuated longevity pathway activation — the opposite of what the established longevity-associated G alleles at rs2802292 and rs2764264 achieve.

The ²² GWAS Catalog records additional associations for rs2153960 including cortical thickness (G allele, p = 3 × 10⁻¹⁶) and subcortical brain volumes — associations likely reflecting LD with nearby FOXO3 regulatory variants that influence brain-expressed FOXO3 activity, consistent with FOXO3's documented role in neuronal stress resistance and cognitive aging.

The Evidence

The primary evidence for rs2153960 is metabolic, not longevity-specific. The FOXO3 locus as a whole is one of the most replicated longevity signals in human genetics — the rs2802292³³ rs2802292
the primary FOXO3 longevity variant with a characterized HSF1-binding mechanism variant has been replicated in every human population studied. rs2153960 tags this same locus but is a distinct regulatory signal: it is correlated with IGF-1 levels but is NOT the functional longevity variant itself.

Bao et al. 2014⁴⁴ Bao et al. 2014
Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 examined 11 independent FOXO3 longevity studies and explicitly found "no association between rs2153960, rs7762395 or rs13220810 polymorphisms and longevity," while confirming associations for rs2802292, rs2764264, rs13217795, rs1935949, and rs2802288. This establishes rs2153960 as a metabolic biomarker variant at the FOXO3 locus rather than a direct longevity variant in its own right.

This distinction matters for interpretation. The variant's value is contextual: it captures variation in IGF-1 signaling tone that may modify how effectively FOXO3's protective mechanisms operate across decades. Notable population frequency differences — the A allele is common (~70%) in Europeans and East Asians but rare (~17%) in Africans — suggest this variant arose or rose to high frequency in non-African populations through mechanisms that may relate to historical differences in nutrition or growth environments, though this is speculative.

Practical Implications

For individuals carrying the AA or AG genotype (the common pattern in most non-African populations), the relevant consideration is that their FOXO3 locus may be tagging a higher-IGF-1 regulatory state. This makes lifestyle interventions that lower IGF-1 and directly activate FOXO3 especially relevant — caloric restriction, protein cycling (lower animal protein), and extended fasting all reliably reduce IGF-1 and restore FOXO3 nuclear access.

For GG carriers (the ancestrally enriched genotype, most common in individuals of African ancestry), the locus tags a lower-IGF-1 regulatory state that may represent better baseline FOXO3 activation capacity. This is consistent with the well-established principle in longevity biology that lower-normal IGF-1 (100–150 ng/mL) is associated with healthier aging trajectories.

In all cases, the evidence-based interventions for supporting FOXO3 signaling — fasting, plant-protein diets, resistance training, and HIIT — remain the most actionable tools, regardless of genotype at this locus.

Interactions

rs2153960 is located in the same 101,625 base-pair FOXO3 intron 2 that harbors rs2802292 (the primary longevity variant whose G allele creates an HSF1 binding site) and rs12212067 (the MZF1-binding anti-inflammatory variant). The mechanisms are distinct: rs2802292 adds a stress-activated enhancer, while rs2153960 tags IGF-1 regulatory capacity. Together, these provide a more complete picture of FOXO3 regulatory architecture than any single variant alone. Carriers who are GG at rs2153960 (lower IGF-1 tone) AND GG at rs2802292 (enhanced stress-response FOXO3 activation) would have the most favorable combined FOXO3 regulatory state.

The rs35767⁵⁵ rs35767
IGF-1 promoter variant independently affecting IGF-1 transcription in the IGF1 gene itself provides complementary information about the IGF-1/FOXO3 axis from the ligand side; individuals with low-IGF-1 variants at both the IGF1 locus and the FOXO3 locus may have particularly robust FOXO3 pathway activation.

ABCG1 (ATP-binding cassette transporter G1¹¹ ATP-binding cassette transporter G1
a membrane protein that pumps cholesterol from macrophages and other peripheral cells onto HDL particles in the bloodstream) is one of two key transporters that drive reverse cholesterol transport — the pathway that clears excess cholesterol from arterial walls and returns it to the liver for disposal. rs2234714 sits in an intronic region of the ABCG1 gene approximately 768 base pairs upstream of a transcribed region, tagging the same chromosomal segment as other ABCG1 promoter variants that have been linked to coronary artery disease (CAD) susceptibility.

The variant does not appear to alter ABCG1 transcription directly — a luciferase reporter assay found no functional effect from this specific position. Its CAD association is therefore most likely due to linkage disequilibrium²² linkage disequilibrium
the non-random co-inheritance of nearby alleles, so that rs2234714 tracks alongside a functionally important nearby variant without itself causing the effect with functionally relevant variants at the ABCG1 promoter locus, particularly rs57137919 (-367G>A).

The Mechanism

ABCG1 acts as the second-wave transporter in the two-step cholesterol efflux relay. ABCA1³³ ABCA1
ATP-binding cassette transporter A1, which initiates reverse cholesterol transport by loading nascent HDL particles starts the process by attaching cholesterol and phospholipids to lipid-poor apolipoprotein A-I. ABCG1 then continues the relay, pumping additional cholesterol onto these maturing HDL particles and enabling them to carry larger cholesterol loads back to the liver.

A functional study of the nearby rs57137919 promoter variant⁴⁴ functional study of the nearby rs57137919 promoter variant
Liu et al. ABCG1 rs57137919G>A polymorphism is functionally associated with varying gene expression and apoptosis of macrophages. PLoS One, 2014 demonstrated that reduced ABCG1 expression at this locus causes approximately 23% less cholesterol efflux to HDL in macrophages and a 2-fold increase in apoptosis of cholesterol-loaded macrophages — hallmarks of impaired plaque clearance. While rs2234714 did not show the same functional signal in reporter assays, it resides on the same genomic segment and tracks alongside this biologically meaningful variation.

Beyond lipid transport, ABCG1 also suppresses the NLRP3 inflammasome⁵⁵ ABCG1 also suppresses the NLRP3 inflammasome
Westerterp et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation, 2018 in macrophages and monocytes. When cholesterol efflux is impaired, intracellular cholesterol accumulation triggers inflammatory cytokine release (IL-1β, IL-18) independently of circulating HDL-C — meaning ABCG1 variants can raise cardiovascular risk through inflammation, not just through lipid channels.

The Evidence

The primary association study⁶⁶ primary association study
Xu et al. A polymorphism in the ABCG1 promoter is functionally associated with coronary artery disease in a Chinese Han population. Atherosclerosis, 2011 enrolled 1,021 CAD patients and 1,013 controls from a Han Chinese cohort. The rs2234714 A allele was associated with reduced CAD risk in a recessive model (adjusted OR 0.64, p = 0.015), meaning AA homozygotes had approximately 36% lower odds of CAD compared to G-allele carriers. Importantly, the authors found no functional effect of this specific variant in promoter reporter assays, suggesting the association is driven by LD with the functionally active rs57137919 variant rather than by rs2234714 itself.

The evidence is currently limited to this single study in one population. No large European GWAS or replication cohort has independently confirmed the rs2234714 CAD signal. This places the evidence at the emerging level until replicated in independent populations.

A comprehensive pharmacological review⁷⁷ comprehensive pharmacological review
Frambach et al. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacol Rev, 2020 reinforces the broader biological relevance of the ABCG1 locus: reduced transporter expression is rate-limiting for reverse cholesterol transport, and pharmacological enhancement of ABCG1 activity is an active therapeutic research direction for atherosclerosis prevention.

Practical Actions

Because rs2234714 is likely a tagging variant, its most actionable implication is that G-allele homozygotes may carry a slightly higher burden of risk variants at the ABCG1 promoter locus. Supporting ABCG1-mediated cholesterol efflux through dietary and lifestyle approaches has the same mechanistic rationale here as for other ABCG1 variants. Omega-3 fatty acids (EPA/DHA) upregulate ABCG1 expression in macrophages through PPAR-gamma and LXR signaling pathways. Monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency is warranted for GG homozygotes.

Interactions

rs2234714 lies on the same ABCG1 haplotype block as rs1044317 (3'UTR regulatory variant) and rs57137919 (promoter variant with documented functional effects on expression and macrophage cholesterol efflux). Individuals carrying risk haplotypes spanning multiple ABCG1 variants may have greater cumulative impairment of cholesterol efflux than any single variant predicts. ABCA1 variants (rs2853579, rs4149268) affect the first step of the same cholesterol efflux relay, and compound effects across the ABCA1–ABCG1 pathway are biologically plausible.

PSCA¹¹ PSCA
Prostate stem cell antigen — a GPI-anchored cell surface glycoprotein of the Ly-6/uPAR superfamily; despite its name it is widely expressed in gastric, bladder, pancreatic, and intestinal epithelia, not just the prostate is a protein that decorates the surface of gastric epithelial cells and has roles in controlling cell proliferation, adhesion, and the epithelial response to bacterial colonisation. rs2294008 sits in the 5′ UTR²² 5′ UTR
The untranslated region immediately upstream of the coding sequence; variants here can alter promoter activity and mRNA stability without changing the protein itself of PSCA, and the T allele at this position creates a binding site for a transcriptional repressor that silences the gene. The result: less PSCA on the gastric surface, a weakened epithelial barrier, and a meaningfully elevated risk of diffuse-type gastric cancer³³ diffuse-type gastric cancer
One of the two major histological subtypes; diffuse-type infiltrates the stomach wall without forming a discrete mass, tends to arise in younger individuals, and carries a worse prognosis than intestinal-type gastric cancer.

The Mechanism

The T allele at rs2294008 generates a consensus recognition sequence for YY1⁴⁴ YY1
Yin Yang 1 — a ubiquitous Polycomb-group transcription factor that can act as either an activator or a repressor depending on its co-factors; at the PSCA promoter it recruits Polycomb repressive complexes within 200 base pairs of the PSCA transcription start site. Functional studies demonstrated that this YY1 binding site is sufficient to suppress promoter activity: when the binding sequence was disrupted experimentally, transcriptional activity was fully restored to the level seen with the C allele. In gastric tissue from T/T homozygotes, PSCA mRNA and protein are demonstrably lower than in C/C individuals.

Helicobacter pylori compounds the genetic suppression. The bacterium independently downregulates PSCA expression (p = 5.1 × 10⁻⁸ across paired infected and eradicated samples), and T allele carriers show a steeper drop in PSCA protein specifically in severe gastritis compared to mild gastritis — a pattern not seen in C/C individuals. When H. pylori eradication therapy is given, PSCA expression partially recovers, but T allele carriers begin from a lower baseline. This additive suppression creates a dual vulnerability: less surface PSCA to regulate epithelial proliferation, and a more permissive microenvironment for oncogenic transformation.

The functional consequence matters most for diffuse-type gastric cancer⁵⁵ diffuse-type gastric cancer
Characterised by single cells or small clusters invading the lamina propria rather than forming glands; often called signet ring cell carcinoma in its most extreme form; associated with CDH1 mutations and loss of E-cadherin expression and for gastric mucosal atrophy, an early precancerous lesion. In T/T individuals with confirmed H. pylori infection, the risk of mucosal atrophy — the first step in the Correa cascade toward cancer — is approximately 2.1-fold higher than in C/C individuals.

The Evidence

The foundational study is a two-stage GWAS⁶⁶ two-stage GWAS
Sakamoto H et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nature Genetics, 2008 in Japanese and Korean populations (total >2,100 cases and controls). The allele-specific odds ratio for T in the Korean validation cohort was 1.90 (95% CI 1.56–2.33, p = 8.01 × 10⁻¹¹), with the association confined to diffuse-type and not seen in intestinal-type gastric cancer. Mechanistic follow-up in the same study showed that the T allele region had lower transcriptional activity in reporter assays.

Across European populations, the T allele association was confirmed in a Spanish case-control study⁷⁷ case-control study
García-González MA et al. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer. Int J Cancer, 2015 of 603 gastric cancer patients and 675 healthy controls (OR 1.46 for the T allele; OR 1.59 specifically for diffuse-type). Notably, the T variant was also associated with worse overall survival in diffuse-type patients (hazard ratio 1.85, 95% CI 1.12–3.06), suggesting an effect not only on initiation but on tumour biology.

A meta-analysis⁸⁸ meta-analysis
Geng P et al. Association between PSCA rs2294008 C>T polymorphism and cancer risk. PLoS ONE, 2015 of 21 studies (27,197 cases, 48,237 controls) found TT vs CC OR = 1.18 (95% CI 1.10–1.27) and T allele OR = 1.10 (95% CI 1.06–1.14), with consistent findings across gastric and bladder cancer. The largest pooled analysis⁹⁹ pooled analysis
Wang X et al. Genetic Testing and Molecular Biomarkers, 2023 (45 articles, 37,586 cases, 51,197 controls) confirmed an overall cancer OR of 1.206 for TT vs CC and found that PSCA protein expression was significantly lower in gastric cancer tissue than in adjacent normal mucosa.

The most striking effect size comes from the gene-gene interaction study. Saeki et al. 2011 demonstrated that individuals carrying risk alleles at both rs2294008 (PSCA) and rs4072037 (MUC1) face an OR of approximately 8.38 for diffuse-type gastric cancer — far exceeding the individual effects of either SNP alone.

For bladder cancer, the T allele shows a parallel but weaker association: OR approximately 1.14–1.23 in meta-analyses, with stronger effects in Asian populations. PSCA is expressed on urothelial cells and bladder cancer tissue, consistent with a shared biological mechanism.

Practical Implications

For T allele carriers, the primary actionable target is H. pylori infection. Eradication in infected individuals reduces gastric cancer incidence by roughly 35–45% in the general population; in T allele carriers with already-suppressed PSCA, the absolute benefit is likely higher because the baseline mucosal vulnerability is genetically amplified. The non-invasive urea breath test or stool antigen test is the preferred diagnostic — serology should be avoided because it cannot distinguish active from past infection.

For T/T homozygotes, upper endoscopy is worth discussing with a gastroenterologist, particularly in the presence of any family history of gastric cancer, chronic gastritis symptoms, or residence in a high-incidence region (East Asia, Eastern Europe, parts of Central and South America). Diffuse-type gastric cancer does not reliably pass through detectable precancerous stages visible to the naked eye, so symptom awareness matters between scheduled endoscopies.

Dietary sulforaphane (broccoli sprouts) has direct anti-H. pylori activity and supports Nrf2-mediated mucosal protection through a pathway independent of PSCA expression, making it a relevant complement to surveillance for T allele carriers.

Interactions

The most clinically important interaction is with rs4072037 (MUC1) and its proxy rs2070803 (MUC1). PSCA and MUC1 contribute to complementary mucosal defence mechanisms — PSCA regulates epithelial cell proliferation and adhesion, while MUC1 provides the glycoprotein barrier against bacterial attachment. When both pathways are compromised by risk genotypes, the combined OR of ~8.38 for diffuse-type gastric cancer (Saeki et al. 2011) represents a multiplicative interaction that substantially exceeds the individual signals.

rs2976392 is an intronic PSCA variant in strong linkage disequilibrium with rs2294008 and was the lead SNP in the original Sakamoto 2008 GWAS (OR 1.62 for the Japanese cohort). The two SNPs tag the same risk haplotype; most studies use rs2294008 as the surrogate because it is the functional variant.

H. pylori infection further compounds the genetic risk: the bacterium independently suppresses PSCA expression, and T allele carriers show a disproportionate decline in PSCA with progressive gastritis (OR 3.88 for gastritis severity progression in infected individuals).

The peroxisome is a cellular organelle dedicated in part to processing the fatty acids that mitochondria cannot — very long chains (more than 20 carbons), branched-chain fatty acids such as phytanic acid, and the bile acid precursors derived from cholesterol. D-bifunctional protein (DBP), encoded by HSD17B4, performs two sequential steps in this peroxisomal beta-oxidation¹¹ peroxisomal beta-oxidation
The peroxisomal beta-oxidation spiral shortens very long-chain and branched fatty acids by two carbons per cycle, generating acetyl-CoA and passing the shortened chain to mitochondria for complete oxidation. DBP catalyses the second (hydratase) and third (dehydrogenase) reactions of each cycle pathway. When DBP fails, these substrates accumulate to toxic levels in the nervous system, gonads, and other tissues.

The c.715-1G>A variant destroys the canonical splice acceptor site at the boundary of intron 9 and exon 10. This is not a subtle regulatory tweak — it eliminates a signal the spliceosome depends on to excise intron 9 cleanly. The result is aberrant splicing²² aberrant splicing
Splice acceptor variants at the invariant AG dinucleotide of an intron typically cause exon skipping, intron retention, or activation of cryptic splice sites — all of which produce frameshifted or truncated transcripts that are degraded by nonsense-mediated decay or yield a non-functional protein, essentially silencing that copy of HSD17B4.

The Mechanism

The splice acceptor at the 3′ end of an intron is defined by the invariant AG dinucleotide. The c.715-1G>A change replaces the G at position −1 of the intron 9 acceptor — the last nucleotide before the exon begins. This position is part of the [polypyrimidine-tract/AG motif | The spliceosomal U2AF complex recognises the polypyrimidine tract and the invariant AG to position the 3′ splice site. Even a single nucleotide change at the −1G position can completely abolish recognition] that the spliceosome recognises. Disrupting it prevents correct intron removal; the downstream exon is skipped or the intron is retained, and the altered transcript is either degraded by [nonsense-mediated decay | NMD is a cellular surveillance mechanism that degrades mRNAs containing premature stop codons — including those produced by exon skipping with frameshift] or produces a severely truncated, inactive protein. Because DBP is a bifunctional enzyme, loss of either catalytic domain blocks the entire beta-oxidation of very long-chain fatty acids, causing accumulation of C26:0, pristanic acid, and [bile acid intermediates | Di- and trihydroxycholestanoic acid (DHCA and THCA) are intermediates in bile acid synthesis that require peroxisomal oxidation by DBP to become chenodeoxycholic and cholic acid. In DBP deficiency these intermediates accumulate in plasma and urine] in plasma and tissues.

The Evidence

The association of HSD17B4 null alleles with fatal peroxisomal disease has been established across decades of case series and biochemical studies. Ferdinandusse et al. 2006 characterised 110 patients with DBP deficiency, identifying 61 distinct mutations³³ Ferdinandusse et al. 2006 characterised 110 patients with DBP deficiency, identifying 61 distinct mutations
Ferdinandusse et al. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. Am J Hum Genet. 2006;78(1):112-24. The defining genotype-phenotype rule across this cohort: residual enzyme activity predicts survival. Patients carrying two null alleles (including splice-site variants) showed no detectable DBP activity and the most severe neonatal phenotype — hypotonia, seizures, absent psychomotor development, and death typically within the first two years of life.

The discovery that milder HSD17B4 alleles cause Perrault syndrome rather than neonatal death came from whole-exome sequencing. Pierce et al. 2010 identified the first compound heterozygous HSD17B4 family⁴⁴ Pierce et al. 2010 identified the first compound heterozygous HSD17B4 family
Pierce et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault syndrome. Am J Hum Genet. 2010;87(2):282-288: two sisters with sensorineural hearing loss, primary ovarian insufficiency, and ataxia — none of whom had the catastrophic neonatal course. Their mutations reduced but did not abolish DBP activity. This established that heterozygous carriage of one null allele (like a splice-site variant) paired with one hypomorphic allele produces a survivable but multisystem disorder. A splice-site null paired with a second null allele, by contrast, predicts a severe neonatal presentation.

McMillan et al. 2012 described a fourth clinical subtype (Type IV)⁵⁵ McMillan et al. 2012 described a fourth clinical subtype (Type IV) in two brothers with adult-onset cerebellar ataxia, peripheral neuropathy, and hearing loss — but normal plasma VLCFA levels. Their compound heterozygous mutations each reduced but did not abolish a single catalytic domain, leaving enough combined activity to avoid neonatal disease while producing progressive neurodegeneration in adulthood. This case underscores that negative plasma VLCFA screening does not exclude HSD17B4-deficiency when one allele is a hypomorph.

Werner et al. 2022 (PMID 34623748)⁶⁶ Werner et al. 2022 (PMID 34623748) reported a neonate with two HSD17B4 splice variants confirmed by RNA sequencing to cause exon 14 skipping, documenting virtually absent DBP activity in fibroblasts and an expanded phenotype that included persistent hypoglycemia — a then-novel finding that broadens the clinical spectrum.

Practical Actions

For individuals heterozygous for c.715-1G>A: carrier status is clinically silent but carries a 25% risk of an affected child if a partner also carries a pathogenic HSD17B4 allele. Genetic counselling and partner testing are the actionable steps. Carrier status alone does not cause accumulation of VLCFA or any known biochemical abnormality.

For individuals who are compound heterozygous (one c.715-1G>A allele plus one additional pathogenic allele): the clinical picture depends critically on the second allele's residual activity. Genetic counselling, metabolic specialist referral, and biochemical testing (plasma VLCFA, pristanic acid, bile acid intermediates; fibroblast DBP enzyme assay if plasma is normal) are the cornerstones of diagnosis. No disease-modifying therapies exist; management is supportive.

Interactions

This variant functions as a null allele at the HSD17B4 locus. Its clinical consequences depend entirely on the genotype at the second allele (compound heterozygosity is the rule for affected patients, since homozygous null variants at HSD17B4 are compatible with survival only in the case of residual activity from other mechanisms). Related SNPs already in the GeneOps database include rs137853096 (Gly16Ser, dehydrogenase domain) and rs137853097 (Asn457Tyr, hydratase domain) — both pathogenic missense variants in HSD17B4 that can compound with this splice allele.

Important Limitation: According to 23andMe's own geneticists, rs25531 is not reliably genotyped on consumer platforms¹¹ not reliably genotyped on consumer platforms
David Hinds of 23andMe reported that "nearly everyone (99.97%) is getting called as CC, and there is no clear heterozygote cluster" and "the genotype calls for rs25531 on our platform are not meaningful". This SNP requires specialized genotyping methods. If your 23andMe data shows AA for rs25531, it is likely a technical artifact rather than your true genotype. This article is included for scientific completeness and for users who have obtained clinical genotyping.

The serotonin transporter gene SLC6A4²² serotonin transporter gene SLC6A4
encodes the protein responsible for clearing serotonin from synapses is one of the most studied genes in psychiatry. The well-known 5-HTTLPR insertion/deletion polymorphism in the gene's promoter has been linked to depression, anxiety, and antidepressant response³³ depression, anxiety, and antidepressant response
though results have been inconsistent across studies for decades. But rs25531, a single nucleotide A→G substitution located within the long (L) allele of 5-HTTLPR, adds a critical layer of complexity: it effectively converts an L allele to function like the short (S) allele⁴⁴ it effectively converts an L allele to function like the short (S) allele
when G is present at rs25531, the L allele has transcriptional activity comparable to the S allele rather than high activity.

The Mechanism

The 5-HTTLPR polymorphism consists of a 44-base-pair insertion/deletion in the SLC6A4 promoter region, creating short (S, 14 repeats) and long (L, 16 repeats) variants. Early research suggested the L allele produced 2-3 times more serotonin transporter mRNA than the S allele⁵⁵ Early research suggested the L allele produced 2-3 times more serotonin transporter mRNA than the S allele
Lesch et al. Science, 1996. However, rs25531 revealed that not all L alleles are functionally equivalent⁶⁶ rs25531 revealed that not all L alleles are functionally equivalent
Hu et al. identified that an A→G substitution at rs25531 within the L allele creates a binding site for the AP-2 transcription factor.

The result is a triallelic system: L_A (L allele with A at rs25531) has high transporter expression, while L_G (L allele with G at rs25531) has low expression similar to the S allele⁷⁷ L_G (L allele with G at rs25531) has low expression similar to the S allele
the G variant disrupts transcription factor binding, reducing promoter activity. This creates a functional hierarchy: L_AL_A > L_AS > L_AL_G > L_GL_G ≈ L_GS > SS in terms of serotonin transporter expression.

The Evidence

The G allele frequency varies dramatically by ancestry⁸⁸ The G allele frequency varies dramatically by ancestry
European-Americans: 7.5%, African-Americans: 21%, reflecting significant population stratification. In the largest study to date of 954 African-American and 2,622 European-American subjects⁹⁹ the largest study to date of 954 African-American and 2,622 European-American subjects
Odgerel et al. Translational Psychiatry, 2013, the G allele was nearly three times more common in African-Americans, and when 5-HTTLPR and rs25531 were combined into high- and low-transcription haplotypes, African-Americans showed significantly fewer low-transcription variants overall.

The clinical significance remains controversial and inconsistent¹⁰¹⁰ controversial and inconsistent
multiple meta-analyses have produced conflicting results. Some studies suggest that individuals with L_AL_A genotypes respond better to SSRIs¹¹¹¹ individuals with L_AL_A genotypes respond better to SSRIs
particularly in Caucasian populations, though effect sizes are modest, while others find no association between rs25531 and treatment outcome¹²¹² no association between rs25531 and treatment outcome
four large studies including STAR*D analyses found no predictive value.

One study found that SSRI serum concentrations correlated with response only in L_A carriers¹³¹³ One study found that SSRI serum concentrations correlated with response only in L_A carriers
suggesting dose-dependent effects specific to the high-expression genotype. Intriguingly, rs25531 also influences opioid analgesia¹⁴¹⁴ rs25531 also influences opioid analgesia
individuals with low-expression genotypes (SA/SA or SA/L_G) showed significantly better pain relief from remifentanil than L_AL_A individuals, suggesting the variant affects multiple neurotransmitter-related drug responses.

Practical Implications

The primary clinical question is whether rs25531 genotyping improves antidepressant selection beyond 5-HTTLPR alone. Current evidence suggests limited additional predictive value¹⁵¹⁵ Current evidence suggests limited additional predictive value
CPIC does not include rs25531 in its recommendations, and multiple studies found no added specificity. The GeneSight pharmacogenomic test¹⁶¹⁶ GeneSight pharmacogenomic test
a commercial panel for antidepressant selection notes that "more data is needed before the rs25531 SNP can be recommended for use in treatment selection."

However, for individuals with clinically obtained rs25531 genotyping, there are some tentative guidelines: Those with G alleles may experience more side effects from SSRIs¹⁷¹⁷ G alleles may experience more side effects from SSRIs
particularly gastrointestinal symptoms and headaches and may benefit from starting at lower doses or considering non-SSRI alternatives. Medications like mirtazapine, which has minimal serotonin transporter affinity¹⁸¹⁸ Medications like mirtazapine, which has minimal serotonin transporter affinity
showed no impact or even improved response in low-expression genotypes, making them reasonable alternatives.

Interactions

Rs25531 must be interpreted together with 5-HTTLPR, as they are in tight linkage disequilibrium and the G allele is almost always found on the L allele background¹⁹¹⁹ the G allele is almost always found on the L allele background
rarely occurring with the S allele. The triallelic classification (L_A, L_G, S) provides more accurate functional prediction than the biallelic (L, S) system alone. Other SLC6A4 polymorphisms including rs2020933 and STin2²⁰²⁰ Other SLC6A4 polymorphisms including rs2020933 and STin2
also affect transporter expression and may compound with rs25531, though the clinical utility of multi-variant haplotypes remains uncertain.

Gene-environment interactions are also critical²¹²¹ Gene-environment interactions are also critical
the combination of low-expression genotypes and stressful life events appears to increase depression risk more than either factor alone, though this finding has been challenged by large meta-analyses. Epigenetic modifications including DNA methylation of the SLC6A4 promoter²²²² Epigenetic modifications including DNA methylation of the SLC6A4 promoter
may interact with rs25531 genotype to affect both expression and treatment response.

Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory disease, driven by gain-of-function variants in MEFV that destabilize pyrin's normally tight control over the inflammasome. Pyrin¹¹ Pyrin
a 781-amino acid protein expressed in neutrophils, monocytes, and dendritic cells that assembles the pyrin inflammasome and controls caspase-1-mediated IL-1β release; named for the Greek word for fever operates as a conditional alarm sensor — active only when genuine pathogen-derived toxins disable the regulatory Rho GTPase pathway. FMF mutations lower this threshold, triggering unprovoked IL-1β storms that manifest as self-limiting 12–72 hour attacks of fever and serositis. M680I is one of five founder mutations²² founder mutations
mutations that arose in a common ancestral population and persisted as carrier groups migrated across the Mediterranean and Middle East; the five account for ~74% of FMF chromosomes in Armenians, Arabs, Jews, and Turks that collectively define the FMF mutation spectrum.

M680I (c.2040G>C on the coding strand, p.Met680Ile) sits in exon 10 at codon 680 — one of two severity hotspots in pyrin's B30.2 regulatory domain. Touitou (2001)³³ Touitou (2001) described codons 680 and 694 as the "mutational hot-spots" of the gene and found that genotypes combining two mutations within these codons are consistently associated with severe phenotypes. ClinVar classifies all three c.2040G> nucleotide variants (G>C, G>A, G>T) as Pathogenic or Pathogenic/Likely pathogenic across independent submissions, with no conflicts.

The Mechanism

Met680 lies within the B30.2 (SPRY) domain⁴⁴ B30.2 (SPRY) domain
the C-terminal regulatory domain of pyrin that senses effectors of the RhoA GTPase signaling axis; when the Rho pathway is disrupted by bacterial toxins, B30.2 detects this and licenses inflammasome assembly of pyrin, at a position closely adjacent to the codon 694 hotspot occupied by M694V and M694I. In the resting state, the regulatory kinases PKN1 and PKN2 phosphorylate pyrin at S208 and S242, and the 14-3-3 proteins bind to hold the inflammasome inactive. Substituting the bulky, flexible methionine at position 680 with the branched-chain isoleucine alters the local conformation of the B30.2 domain, disrupting the PKN1/14-3-3 regulatory contact. The result is partial constitutive inflammasome activation: caspase-1 cleaves pro-IL-1β and pro-IL-18 without the microbial trigger normally required, producing episodes of sterile inflammation in serosal and joint tissues.

The severity of the M680I dysfunction — while unambiguously pathogenic — is intermediate. Being at codon 680 rather than 694 produces a slightly different disruption geometry than M694V, explaining why M680I homozygotes may have a moderately different colchicine responsiveness profile than M694V homozygotes. However, when M680I is combined with M694V on the opposite chromosome, the compound heterozygous phenotype approaches the severity of M694V homozygosity.

The Evidence

M680I is the second most commonly identified MEFV disease allele in large FMF cohorts. In the largest published pediatric FMF registry — Öztürk et al. 2022⁵⁵ Öztürk et al. 2022, n=3,454 patients — M680I accounted for 11.3% of all disease alleles, compared to 55.3% for M694V and 7.6% for V726A. Exon 10 mutation carriers as a group had earlier disease onset (4.6 vs. 5.6 years for exon 2 carriers) and more frequent attacks. Population genetics meta-analysis (Papadopoulos et al. 2008⁶⁶ Papadopoulos et al. 2008, cumulative dataset) confirmed M680I at 11.4% of disease alleles across Mediterranean populations, with the mutation enriched primarily in Armenian and Turkish founder groups.

The severity framework for M680I is grounded in the codon-hotspot principle. Touitou (2001) established that genotypes combining two mutations at codons 680 and/or 694 reliably produce severe disease. A systematic review by Gangemi et al. 2018⁷⁷ Gangemi et al. 2018 — covering over 280 MEFV variants — confirmed that M680I homozygotes and M680I/M694 compound heterozygotes have severe disease presentations, though precise quantitative severity scores for isolated M680I homozygosity are less thoroughly characterized in the literature than for M694V, reflecting that homozygous M680I patients are outnumbered by M694V homozygotes in most published cohorts (e.g., 3 vs. 7 homozygotes in one Egyptian registry of 426 patients, Al-Haggar et al. 2014⁸⁸ Al-Haggar et al. 2014).

Compound heterozygosity with M694V is the most clinically critical M680I configuration. Barut et al. 2018⁹⁹ Barut et al. 2018 documented that pediatric amyloidosis cases arose in M694V homozygotes and M694V/M680I compound heterozygotes — placing M680I in the same high-risk amyloidosis tier as M694V when combined with a second high-severity allele. Caglayan et al. 2010¹⁰¹⁰ Caglayan et al. 2010 found M680I in 14.5% of disease alleles in their compound heterozygous FMF cohort; overall colchicine effectiveness was 83% regardless of mutation type, suggesting M680I compound heterozygotes are generally colchicine-responsive, though a subset requiring IL-1 inhibitors is enriched for M694V/M680I genotypes.

Practical Implications

For heterozygous carriers of M680I without clinical FMF symptoms, no colchicine treatment is warranted. FMF is autosomal recessive; a single M680I allele is generally insufficient for full-expression disease, though subclinical inflammatory marker elevation has been documented in obligate heterozygotes across the MEFV hotspot mutations. The clinically urgent scenario is the undiagnosed compound heterozygote: a person carrying M680I on one chromosome and M694V (or another pathogenic allele) on the other may develop clinically significant FMF requiring colchicine — and will be missed by single-site testing.

For confirmed FMF patients (homozygous M680I or compound heterozygous), colchicine at 1.0–2.0 mg/day is the standard prophylactic therapy. The target is complete attack suppression AND normalization of inter-attack serum amyloid A (SAA) — the latter is critical because sustained subclinical elevation of SAA drives the reactive AA amyloidosis that historically caused renal failure and death in inadequately treated FMF. Colchicine is highly effective in the majority of M680I patients; the subset with persistent attacks on ≥2 mg/day should be evaluated for IL-1 inhibitor therapy (anakinra or canakinumab).

Periodic urinalysis for proteinuria (every 6 months) is recommended as an early screen for renal AA amyloidosis, per EULAR FMF management guidelines, in all confirmed pathogenic MEFV genotypes.

Interactions

M680I's most clinically important interaction is compound heterozygosity with M694V (rs61752717). The M694V/M680I compound genotype elevates disease severity above what either allele alone might predict in heterozygosity, approaching the severe tier associated with M694V homozygosity. These patients tend to have higher colchicine requirements and are among those most likely to require IL-1 inhibitor escalation.

M680I can also form a compound genotype with V726A (rs28940579). The V726A/M680I combination appears in Arab and Turkish cohorts and produces a moderate phenotype — more active than V726A homozygosity but less severe than M694V-containing compound genotypes. Compared with M694V/M680I, V726A/M680I disease course is more manageable on standard colchicine doses.

For any M680I heterozygote presenting with FMF-like symptoms, a comprehensive MEFV panel covering all common exon 10 mutations (M694V, M694I, V726A) and E148Q (rs3743930) is the necessary next step before concluding that M680I heterozygosity alone explains the phenotype.

Inside every vascular endothelial cell and platelet-producing megakaryocyte, a molecular sorting system routes proteins to exactly where they need to go. SNX24 — sorting nexin 24¹¹ SNX24 — sorting nexin 24
a member of the PX-domain sorting nexin family; binds phosphoinositide lipids on endosomal membranes and guides cargo vesicles through the intracellular trafficking network — is one component of this system, specifically required for building platelet alpha-granules and regulating endothelial cytokine output. The rs30021 variant lies deep within the SNX24 gene (c.249+4040G>A), in a non-coding intron region that may influence how much SNX24 is produced in vascular tissues.

While rs30021 itself has not been the direct subject of a published clinical trial, it sits in a biologically rich locus. SNX24's documented roles — controlling von Willebrand factor (VWF) release from platelets and modulating the endothelial inflammatory response — are directly relevant to cardiovascular and venous disease. The G allele of rs30021 is uncommon globally (~23% allele frequency), with marked variation across ancestries: European populations carry it at ~31%, East Asian populations at just ~1%.

The Mechanism

SNX24 acts in the alpha-granule maturation pathway²² alpha-granule maturation pathway
alpha-granules are the most abundant organelle in platelets, storing key hemostatic proteins including VWF, P-selectin, fibrinogen, and platelet factor 4 of megakaryocytes — the bone marrow precursor cells that produce platelets. When SNX24 is knocked out experimentally, megakaryocytes accumulate empty membrane vesicles, fail to form mature multivesicular bodies, and produce platelets that are severely depleted in alpha-granule cargo including VWF and CD62P (P-selectin). These proteins are critical for the initial steps of hemostasis and thrombus formation at sites of vascular injury.

In endothelial cells, SNX24 plays a second, independent role: modulating the inflammatory cytokine response to bacterial lipopolysaccharide. When SNX24 expression is suppressed, endothelial cells produce significantly less IL-1β, IL-6, and IL-8 in response to inflammatory signals. This positions SNX24 as a regulator of endothelial activation — the cellular process that initiates leukocyte recruitment, promotes coagulation, and drives the vascular inflammatory response underlying atherosclerosis and venous wall remodeling.

The rs30021 intronic variant (c.249+4040G>A) does not change the SNX24 protein sequence directly. Deeply intronic variants can influence gene expression through effects on splicing enhancers, intronic regulatory elements, or chromatin accessibility. Whether rs30021 affects SNX24 expression in endothelial or megakaryocyte lineages has not been characterized experimentally.

The Evidence

The direct evidence for rs30021 is limited: no published GWAS hit, no ClinVar entry, and no primary study investigating its phenotypic consequence. It appears in the related-variant set of the VEGFA/5q region varicose vein GWAS context, identified in Ahmed et al. 2022³³ Ahmed et al. 2022
two-stage analysis across 810,000 participants identifying 49 genome-wide significant varicose vein loci.

The biological evidence for SNX24's vascular role is stronger. Lacey et al. 2022⁴⁴ Lacey et al. 2022
CRISPR-Cas9 knockout in iPSC-derived megakaryocytes; n=3 cell lines per condition demonstrated that SNX24 loss eliminates alpha-granule maturation, with direct measurement of VWF reduction — a key coagulation factor also implicated in venous thromboembolism. A separate genetic study Lin et al. 2013⁵⁵ Lin et al. 2013
262 Kawasaki disease patients, 76 with coronary artery aneurysm showed that SNX24 variant rs28891 (a different coding variant in the same gene) associates with coronary artery aneurysm severity, and that endothelial cells with reduced SNX24 expression produce less IL-1β, IL-6, and IL-8 — directly connecting SNX24 function to vascular inflammation.

Given the indirect nature of evidence for rs30021 specifically, this SNP is rated emerging. The classification may be upgraded if eQTL studies confirm that rs30021-G reduces SNX24 expression in vascular or platelet precursor tissues.

Practical Actions

For G allele carriers, the theoretical concern is reduced SNX24 expression in two cell types: megakaryocytes (platelets) and endothelial cells. Reduced SNX24 in megakaryocytes could impair alpha-granule loading, affecting VWF release and platelet adhesion capacity at vascular injury sites. Reduced SNX24 in endothelium could reduce inflammatory cytokine output — a potentially protective effect that makes the directionality of this variant complex.

Monitoring VWF levels (including VWF antigen and activity) can capture downstream effects of platelet alpha-granule dysfunction. VWF Ag below 50% is defined as von Willebrand disease type 1, though this is generally driven by VWF gene variants; moderately low VWF activity (50–100%) influences both bleeding tendency and, paradoxically, cardiovascular risk stratification.

Interactions

rs30021 is listed as a co-variant alongside rs11967262 — a VEGFA upstream regulatory variant strongly associated with varicose veins through the 6p21.1 locus. The co-listing reflects their co-occurrence in varicose vein genetic research rather than physical LD (they are on different chromosomes: rs30021 on chr5, rs11967262 on chr6). Their functional connection is through the shared biological theme of vascular wall integrity and endothelial growth factor signaling.

Another SNX24 variant, rs28891, was specifically associated with coronary artery aneurysm risk in Kawasaki disease. Individuals carrying rs30021-G who also have other variants affecting VWF production (VWF gene variants) or platelet function may have compound effects on hemostasis worth discussing with a hematologist.

The IL2RA locus¹¹ IL2RA locus
IL2RA on chromosome 10p15.1 encodes CD25, the alpha subunit of the high-affinity interleukin-2 receptor, essential for Treg development and maintenance is one of the most replicated non-HLA autoimmune susceptibility regions in the human genome. While rs2104286 is the most commonly cited variant at this locus, fine-mapping studies have established that multiple independent genetic signals coexist in the same region, each tagging distinct regulatory effects on IL-2 receptor expression and immune tolerance. rs3134883 is one of these independent signals — it anchors a five-variant haplotype block with its own disease associations and its own relationship to soluble IL-2 receptor biology.

The Mechanism

rs3134883 sits in an intron of IL2RA at chromosome 10, position 6,058,762 (GRCh38). The IL2RA gene lies on the minus strand, but the variant is always reported in plus-strand notation (G/A) as per the GRCh38 reference. It is not a coding change; rather, it is an intronic tag SNP²² intronic tag SNP
Intronic variants can influence gene expression through effects on transcription factor binding, RNA splicing, chromatin accessibility, or enhancer activity within introns that marks a haplotype block in strong linkage disequilibrium with functional regulatory elements.

The five-variant protective haplotype H5 — comprising rs3134883 (G allele), rs3118470, rs7072793, rs4749955, and rs12251307 — tags a protective IL2RA regulatory state³³ tags a protective IL2RA regulatory state
The H5 haplotype was in perfect LD (r²=1.0) with the minor allele of ss52580101 in CEU populations, a variant associated with altered IL-2RA expression and soluble receptor shedding. The G allele at rs3134883 is the protective allele: carriers of the G-containing haplotype have lower autoimmune disease risk. Conversely, the A allele tags a haplotype block associated with altered IL-2 receptor biology — specifically, with changes to the balance between membrane-bound and soluble IL-2RA that reduce effective IL-2 signaling to regulatory T cells.

Mechanistically, impaired IL-2 signaling through the high-affinity receptor complex (CD25/IL-2Rβ/γc) reduces STAT5 phosphorylation⁴⁴ reduces STAT5 phosphorylation
pSTAT5 is the master downstream signal in Tregs; its reduction impairs FoxP3 expression and Treg suppressive capacity in CD4+CD25+ regulatory T cells, lowering their suppressive capacity. A study in genotype-selected healthy donors confirmed that susceptible IL2RA haplotypes reduce IL-2 responsiveness⁵⁵ susceptible IL2RA haplotypes reduce IL-2 responsiveness
Cerosaletti et al. measured lower pSTAT5a and reduced FOXP3 expression in susceptibility-haplotype carriers versus protective-haplotype carriers and reduce FoxP3 expression, directly linking locus-level genetic variation to Treg function.

The Evidence

The Type I Diabetes Genetics Consortium study⁶⁶ Type I Diabetes Genetics Consortium study
5,003 T1D-affected sib-pair families from a large international consortium, 69 SNPs spanning ~88 kb of IL2RA established rs3134883's place in the IL2RA haplotype architecture. The protective H5 haplotype carrying the G allele showed OR 0.699 (95% CI 0.602–0.811, p=3.2×10⁻⁵) for T1D protection. Crucially, rs3134883 retained independent statistical significance (p=4.29×10⁻³) after conditioning on the full H5 haplotype, suggesting it tags both haplotype-level and potentially position-specific regulatory effects.

For rheumatoid arthritis, rs3134883 is among the lead variants at the IL2RA locus in large-scale GWAS. A multi-ancestry RA GWAS⁷⁷ multi-ancestry RA GWAS
Ishigaki et al. meta-analysis across European and East Asian populations, confirming multiple independent IL2RA signals with OR ~1.1 per A allele at rs3134883 confirmed the A allele at rs3134883 reaches genome-wide significance (p as low as 2×10⁻¹⁵ in the Ha et al. 2020 analysis) with OR approximately 1.1 per allele for seropositive RA. This effect is independent from rs2104286, reflecting the well-established multi-signal architecture⁸⁸ multi-signal architecture
Fine-mapping of IL2RA identifies at least three independent association signals affecting T1D and MS through different molecular pathways of the IL2RA locus.

In vitiligo, a GWAS of Chinese Han participants⁹⁹ GWAS of Chinese Han participants
6,857 vitiligo cases and 12,025 controls in a two-stage replication study confirmed the 10p15.1 locus — encompassing rs3134883 — as a susceptibility locus (OR 1.11, p=1.01×10⁻⁵), demonstrating that the IL2RA risk haplotype extends beyond European-ancestry autoimmune diseases. Lymphocyte count modulation by rs3134883 has also been reported in GWAS (p=2×10⁻²¹), consistent with the locus's role in regulating the size and activation state of T-cell populations.

Practical Implications

The A allele at rs3134883 marks a modest but independently established increase in autoimmune disease susceptibility across multiple diseases — RA, T1D, and vitiligo. Its effect is additive: AA homozygotes carry approximately twice the incremental risk of a single A allele. Because this variant reflects impaired IL-2-driven Treg signaling, the same compensatory strategies relevant to rs2104286 apply here: strategies that shore up Treg function through IL-2-independent pathways.

Vitamin D is particularly relevant because 1,25-dihydroxyvitamin D3 promotes Treg differentiation through the VDR/TGF-β1 pathway independently of IL-2 signaling. Clinical evidence¹⁰¹⁰ Clinical evidence
Prietl et al. demonstrated that vitamin D supplementation increases Treg percentages in healthy subjects through the VDR/PLC-γ1/TGF-β1 axis confirms this pathway directly increases FoxP3+ Treg numbers and function, directly addressing the Treg deficit caused by impaired IL-2 signaling.

For RA specifically, knowledge of IL2RA genotype has implications for treatment response monitoring. IL2RA variation influences lymphocyte counts and immune activation set-points, potentially affecting responsiveness to biologics targeting the TNF or IL-6 pathways. Carriers of the A allele should be attentive to early joint symptoms (morning stiffness, bilateral symmetric joint pain) that may signal early RA before structural damage develops.

Interactions

rs3134883 operates in the same IL2RA locus as rs2104286 and rs2256774, but fine-mapping studies¹¹¹¹ fine-mapping studies
Todd et al. and subsequent work confirm at least three independent signals at IL2RA, with distinct effects on sIL-2RA production, surface CD25 expression, and downstream T-cell signaling establish these as distinct signals with partially non-overlapping effects. Carrying risk alleles at multiple IL2RA variants likely compounds Treg signaling impairment beyond what any single variant predicts. Interactions with CTLA4 rs3087243 (immune checkpoint) and PTPN22 rs2476601 (T-cell activation threshold) are biologically plausible as parallel pathways to Treg and effector T-cell dysregulation.